Executive Summary

Oct 2019
PROSPECTS
Consumers favour topical analgesics/anaesthetic to systemic formats

An increasing number of consumers in the Czech Republic are reducing their consumption of systemic analgesics in favour of topical alternatives, which are perceived to be a safer option for self-medication. The gradual shift from systemic analgesics towards topical analgesics/anaesthetic is set to continue over the forecast period as consumers increasingly opt for healthier lifestyles and try to limit their intake of systemic drugs.

Paediatric analgesics continues to suffer from declining sales due to supply issues

Paediatric analgesics are largely purchased for children suffering from acute short-term illnesses such as fever, moderate pain or ear infections, and parents seek a gentle solution to relieve their discomfort. Generally, oral suspension is preferred for infants, whilst suppositories and tablets are more convenient to use for older children.

Adult aspirin witnesses an improved retail value performance as manufacturers stimulate sales

After a flat average retail value performance over the review period, adult aspirin returned to moderate growth in 2019, largely driven by innovation in packaging, increasing marketing efforts and the strong performance of private label products, which entered the category in 2017. Brands also innovated in adult aspirin, further renewing interest in these products.

COMPETITIVE LANDSCAPE
Sanofi retains its strong lead despite a product withdrawal

Sanofi retained its strong lead in analgesics in 2019 despite the withdrawal of Ibalgin Baby due to the suspicion that a foreign substance may be present in a specific batch, which had been on the market since mid-October 2018. It has been estimated that about 1,660 drug packages had been circulated to pharmacies or patients.

GlaxoSmithKline and Pfizer join forces in OTC

The former GlaxoSmithKline and Pfizer are joining forces in OTC with the announcement of a joint venture. The new OTC business is expected to have revenues of approximately GBP9.

The penetration of private label continues

New product development in analgesics is limited, focusing mainly on new faster-acting variants of existing brands. However, the leading pharmacy chain, Ceska Lekarna Holding, (Dr Max) introduced its Parapyrex Combi private label line in 2018 to replace its existing Paracetamol Dr Max.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in the Czech Republic

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in Czech Republic with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in Czech Republic, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in Czech Republic market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in Czech Republic?
  • What are the major brands in Czech Republic?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in the Czech Republic - Category analysis

HEADLINES

PROSPECTS

Consumers favour topical analgesics/anaesthetic to systemic formats
Paediatric analgesics continues to suffer from declining sales due to supply issues
Adult aspirin witnesses an improved retail value performance as manufacturers stimulate sales

COMPETITIVE LANDSCAPE

Sanofi retains its strong lead despite a product withdrawal
GlaxoSmithKline and Pfizer join forces in OTC
The penetration of private label continues

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in the Czech Republic - Industry Overview

EXECUTIVE SUMMARY

Self-medication and prevention bring a further boost to consumer health, with an emphasis on natural remedies
Another year of growth in 2019
Consumer confidence in private label products continues to increase
Internet retailing continues to grow, while some pharmacies struggle to get supplies
An even stronger performance for the forecast period

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Life Expectancy at Birth 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019

DEFINITIONS

SOURCES

Summary 2 Research Sources